Opioid Risk Management: FDA Not Impressed With Industry Working Group's Proposals
This article was originally published in The Pink Sheet Daily
Executive Summary
After a meeting that produced little aside from a suggestion that DEA may be able to track physician training, has industry lost its chance to craft a REMS for the pain products?
You may also be interested in...
FDA Finalizing Opioid REMS Proposal, Sets Joint Advisory Committee Meeting For July
FDA wants to gather feedback from advisors and from the public on the classwide REMS for opioid analgesics, and judging from the stakeholder meetings the agency has held so far, it will get an earful.
FDA Finalizing Opioid REMS Proposal, Sets Joint Advisory Committee Meeting For July
FDA wants to gather feedback from advisors and from the public on the classwide REMS for opioid analgesics, and judging from the stakeholder meetings the agency has held so far, it will get an earful.
Acurox Panel Review Complicated By FDA's Uncertainty Over How Much Evidence Is Needed To Prove Abuse Deterrence
FDA is not convinced that additives meant to make the immediate-release oxycodone formulation difficult to ingest, snort or inject will have their intended deterrent effect.